Dosing regimes for treatment of synucleinopathies

USPTO granted patent US12595295B2 to Prothena Biosciences Limited for dosing regimes treating synucleinopathies. The patent claims cover two intravenous antibody dosing regimens: 3000-5000 mg administered every 3-5 weeks, and 1300-1700 mg administered every 3-5 weeks. The 13 claims protect specific dosing protocols for neurological conditions involving alpha-synuclein aggregation.\n\nBiopharmaceutical companies developing antibody therapeutics for Parkinson's disease and related neurological disorders should conduct freedom-to-operate analyses to assess potential patent overlap. Healthcare providers and clinical researchers evaluating synucleinopathy treatments should consider intellectual property implications when selecting therapeutic regimens. The patent does not restrict clinical practice but establishes commercial exclusivity for the specified dosing protocols.